FIRST LACT

10-8-2018

FDA approves new treatment for a rare genetic disorder, Fabry disease

FDA approved Galafold (migalastat), the first oral medication for the treatment of adults with Fabry disease.

FDA - U.S. Food and Drug Administration

10-8-2018

FDA approves new vaginal ring for one year of birth control

FDA approved Annovera (segesterone acetate and ethinyl estradiol vaginal system), a combined hormonal contraceptive for women of reproductive age used to prevent pregnancy and is the first vaginal ring contraceptive that can be used for an entire year.

FDA - U.S. Food and Drug Administration

10-8-2018

FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease

FDA approves new drug for treatment of polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR). This is the first FDA-approved treatment for this rare, debilitating and often fatal genetic disease and the first FDA approval of a new class of drugs called small interfering ribonucleic acid (siRNA) treatment.

FDA - U.S. Food and Drug Administration

10-8-2018

FDA allows marketing of first direct-to-consumer app for contraceptive use to prevent pregnancy

The app uses basal body temperature readings to predict when a woman is most fertile to help her avoid conceiving on those days if using as a form of contraception

FDA - U.S. Food and Drug Administration

8-8-2018

FDA approves first generic drug under new pathway aimed at enhancing market competition for sole source drugs

FDA approves first generic drug under Competitive Generic Therapy (CGT) designation for products with inadequate generic competition

FDA - U.S. Food and Drug Administration

3-8-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps the agency is taking to support the development of novel nicotine replacement drug therapies to help smokers quit cigarettes

FDA releases the first of two draft guidances aimed at supporting the development of novel, inhaled nicotine replacement therapies that could be submitted for approval as new drugs.

FDA - U.S. Food and Drug Administration

30-7-2018

FDA approves first treatment for rare adrenal tumors

FDA approves first treatment for rare adrenal tumors

FDA - U.S. Food and Drug Administration

27-7-2018

Scientific guideline: VICH GL56 on studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing species: study design recommendations for residue studies in honey for establishing MRLs and withdrawal periods - First versi

Europe - EFSA - European Food Safety Authority EFSA Journal

20-7-2018

FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation

FDA approves new drug for the treatment of adults with acute myeloid leukemia who have a specific genetic mutation and a companion diagnostic to detect specific mutations in the IDH1 gene in patients with AML

FDA - U.S. Food and Drug Administration

18-7-2018

FDA approves first cancer drug through new oncology review pilot that enables greater development efficiency

FDA approves first cancer drug through new oncology review pilot that enables greater development efficiency

FDA - U.S. Food and Drug Administration

13-7-2018

FDA approves the first drug with an indication for treatment of smallpox

FDA today approved TPOXX (tecovirimat), the first drug with an indication for treatment of smallpox.

FDA - U.S. Food and Drug Administration

13-7-2018

Scientific guideline: Guideline on good pharmacogenomic practice - First version, adopted

This guideline provides recommendations for the conduct of genomic studies in relation to medical therapy in order to provide high quality information on the impact of genomic variability on drug response. Primary focus is on the analysis of genomic germline DNA. The analysis of somatic DNA and genomic biomarkers for cancer treatment is not being discussed and might be developed as an Annex or in separate guidance.

Europe - EFSA - European Food Safety Authority EFSA Journal

3-7-2018

Superseded - Community herbal monograph on Cimicifuga racemosa (L.) Nutt., rhizome - First version, adopted

Europe - EMA - European Medicines Agency

25-6-2018

FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy

FDA approved Epidiolex (cannabidiol) oral solution, the first drug comprised of an active ingredient derived from marijuana, to treat two rare and severe forms of epilepsy.

FDA - U.S. Food and Drug Administration

25-6-2018

Launch of the national exploratory measurement campaign for pesticide residues in air

ANSES, INERIS and the network of approved air quality monitoring associations (AASQAs) coordinated by ATMO France are today launching a campaign to measure pesticide residues in air. This first national campaign aims to improve knowledge of the pesticides found in ambient air and thus gain a better understanding of the exposure of the French population. This campaign will ultimately be used to define a surveillance strategy for pesticides in air.  

France - Agence Nationale du Médicament Vétérinaire

22-6-2018

FDA permits marketing of first catheter-based systems used to create vascular access for hemodialysis patients

FDA permits marketing of first catheter-based systems used to create vascular access for hemodialysis patients

FDA - U.S. Food and Drug Administration

21-6-2018

FDA approves first continuous glucose monitoring system with a fully implantable glucose sensor and compatible mobile app for adults with diabetes

glucose monitoring system, implantable glucose sensor, adults, diabetes

FDA - U.S. Food and Drug Administration

14-6-2018

FDA approves first generic versions of Suboxone sublingual film, which may increase access to treatment for opioid dependence

: FDA approved the first generic versions of Suboxone (buprenorphine and naloxone) sublingual film (applied under the tongue) for the treatment of opioid dependence.

FDA - U.S. Food and Drug Administration

6-6-2018

National Network for the Monitoring and Prevention of Occupational Diseases: new data published on cancers of occupational origin

At the 35th French occupational medicine and health congress (CNMST) held in Marseille from 5 to 8 June 2018, ANSES presented for the very first time data on cancers of occupational origin collected by the National Network for Monitoring and Prevention of Occupational Diseases (RNV3P) coordinated by the Agency. These data are used to build up a comprehensive picture of the cancers associated with occupational exposure situations, in order toidentify the industry sectors and situations most at risk, with ...

France - Agence Nationale du Médicament Vétérinaire

4-6-2018

FDA approves first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment

FDA approves Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to decrease the chance of infection as suggested by febrile neutropenia in patients with non-myeloid cancer.

FDA - U.S. Food and Drug Administration

30-5-2018

FDA approves first artificial iris

FDA approves first artificial iris, a surgically implanted device to treat aniridia or other damage to the iris

FDA - U.S. Food and Drug Administration

29-5-2018

TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) by Allergan: Recall - Due to Out of Sequence Capsules

Allergan recently identified, through a physician report, that four placebo capsules were placed out of order in a sample pack of TAYTULLA. Specifically, the first four days of therapy had four non-hormonal placebo capsules instead of active capsules. As a result of this packaging error, oral contraceptive capsules, that are taken out of sequence, may place the user at risk for contraceptive failure and unintended pregnancy. The reversing of the order may not be apparent to either new users or previous ...

FDA - U.S. Food and Drug Administration

29-5-2018

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules

Allergan plc (NYSE:AGN) today issued a voluntary recall in the US market of one lot (Lot# 5620706, Expiry May-2019) of TAYTULLA® (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1mg/20mcg, 6x28 physicians sample pack, indicated for use by women to prevent pregnancy. Allergan recently identified, through a physician report, that four placebo capsules were placed out of order in a sample pack of TAYTULLA. Specifically, the first four days of therapy had four non-hormonal...

FDA - U.S. Food and Drug Administration

25-5-2018

Nosocomial infections can also be caused by the Bacillus cereus bacterium

While Bacillus cereus is well known as a source of food infections, researchers from INRA and ANSES, working with doctors at nine French hospitals[1] including those in the Paris Public Hospital System (AP-HP), have demonstrated for the first time that this bacterium is also responsible for inter- and intra-hospital nosocomial contamination.

France - Agence Nationale du Médicament Vétérinaire

24-5-2018

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

The FDA has approved Semintra (telmisartan oral solution), the first FDA-approved animal drug to control systemic hypertension in cats. Semintra is an oral solution administered either directly into the cat’s mouth or on top of a small amount of food.

FDA - U.S. Food and Drug Administration

22-5-2018

Porsche Cars Canada, Ltd. recalls My First Porsche - Wooden Car (in blue/black)

The wheels and axles of the toy car may come loose and detach, posing a choking hazard to young children.

Health Canada

18-5-2018

Juluca, Tivicay, Triumeq (dolutegravir): FDA to Evaluate - Potential Risk of Neural Tube Birth Defects

Preliminary results from an ongoing observational study in Botswana found that women who received dolutegravir at the time of becoming pregnant or early in the first trimester appear to be at higher risk for these defects. Neural tube defects are birth defects that can occur early in pregnancy when the spinal cord, brain, and related structures do not form properly. To date, in this observational study there are no reported cases of babies born with neural tube defects to women starting dolutegravir lat...

FDA - U.S. Food and Drug Administration

16-5-2018

FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults

FDA approved Lucemyra (lofexidine hydrochloride) for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults.

FDA - U.S. Food and Drug Administration

15-5-2018

FDA approves first epoetin alfa biosimilar for the treatment of anemia

FDA approves Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia

FDA - U.S. Food and Drug Administration

14-5-2018

FDA Approves Mirataz, a New Animal Drug to Manage Undesired Weight Loss in Cats

FDA has approved Mirataz (mirtazapine transdermal ointment), a new animal drug to manage undesired weight loss in cats. Mirataz is the first transdermal product to receive FDA approval for use in cats. FDA-approved drugs have been demonstrated to be safe and effective for their intended use.

FDA - U.S. Food and Drug Administration

11-5-2018

FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients

FDA approves Gilenya (fingolimod) to treat multiple sclerosis MS in children age 10 and older. This is the first FDA approval of a drug to treat MS in pediatric patients

FDA - U.S. Food and Drug Administration

3-5-2018

CVM eSubmitter Webinar 1 Agenda

CVM will host the first of a three-part webinar series to provide information on the use of CVM’s electronic submission tool, eSubmitter, in the new animal drug application approval process. These webinars will support the use of eSubmitter as we move to 100% electronic submission.

FDA - U.S. Food and Drug Administration

30-4-2018

Call for scientific data for the review of the HMPC assessment on <i>Andrographis paniculata</i> Nees, folium - First version, draft: consultation open

Europe - EMA - European Medicines Agency

30-4-2018

Call for scientific data for the review of the HMPC assessment on <i>Angelica sinensis</i> (Oliv.) Diels, radix - First version, draft: consultation open

Europe - EMA - European Medicines Agency

30-4-2018

Call for scientific data for the review of the HMPC assessment on <i>Withania somnifera</i> (L.) Dunal, radix - First version, draft: consultation open

Europe - EMA - European Medicines Agency

30-4-2018

Call for scientific data for the review of the HMPC assessment on <i>Centella asiatica</i> L. Urban, herba - First version, draft: consultation open

Europe - EMA - European Medicines Agency

30-4-2018

Call for scientific data for the periodic review of the monograph on <i>Filipendula ulmaria </i>(L.) Maxim. (= <i>Spiraea ulmaria</i> L.), herba - First version, draft: consultation open

Europe - EMA - European Medicines Agency

30-4-2018

Call for scientific data for the periodic review of the monograph on <i>Filipendula ulmaria</i> (L.) Maxim. (= <i>Spiraea ulmaria</i> L.), flos - First version, draft: consultation open

Europe - EMA - European Medicines Agency

30-4-2018

Call for scientific data for the periodic review of the monograph on <i>Capsella bursa-pastoris</i> (L.) Medikus, herba - First version, draft: consultation open

Europe - EMA - European Medicines Agency

20-3-2018

Medicines Safety Update, Volume 9, Number 1, February-March 2018

First-generation oral sedating antihistamines – use in children, Suvorexant (Belsomra) – next day effects, Desvenlafaxine (Pristiq) recommended dose, Miconazole and potential interaction with warfarin

Therapeutic Goods Administration - Australia

27-10-2017

Keep up with the latest updates on our website

Now you can keep up with all updates on the Danish Medicines Agency's website and not only our news items. You can filter the overview by category and month, and the overview is structured in chronological order with the latest update first. You can find a shortcut to the overview on our home page.

Danish Medicines Agency

2-12-2014

Danish Pharmacovigilance Update, November 2014

Five years ago, we issued Danish Pharmacovigilance Update for the first time. We are delighted to celebrate the newsletter's fifth anniversary with more than 3,000 subscribers to the Danish and the English version, and we hope the interest in Danish Pharmacovigilance Update will continue to grow. You can sign up for the newsletter on our website under News. Among the articles in this issue, you can read about how we have developed the pharmacovigilance activities in the recent years.

Danish Medicines Agency

14-11-2014

Available time slots in Q1 2015 for DCP applications with Denmark as reference member state

Companies wishing to apply for a marketing authorisation for a medicinal product can request a specified submission date (time slot). Time slots are available in the first quarter of 2015.

Danish Medicines Agency

10-2-2014

The common portal for clinical trial applications on DKMAnet still postponed

We plan to launch DKMAnet for clinical trial applications to both the research ethics committees and the Danish Health and Medicines Authority in the first half of 2014.

Danish Medicines Agency

18-12-2006

Reassessment of reimbursement status of the remaining subgroups of ATC group C

The Danish Medicines Agency previously notified companies and a number of scientific societies and patient organisations about which ATC groups and subgroups would be the first to be reassessed, cf. the fact box to the right.

Danish Medicines Agency

18-12-2006

Reassessment of ATC-groups C01, C04 and C05

At its meeting on 19 September 2006, the Reimbursement Committee had its first discussion of the reimbursement status of the following ATC groups.

Danish Medicines Agency

24-4-2006

Reassessment of subgroups in ATC group C

The Danish Medicines Agency is just beginning to reassess the subgroups in ATC group C, medicinal products for the cardiovascular system, and for the first three months of 2006 the agency expects to be working with the following six subgroups.

Danish Medicines Agency

10-8-2018

FDA allows marketing of first direct-to-consumer app for contraceptive use to prevent pregnancy https://go.usa.gov/xUHC6 

FDA allows marketing of first direct-to-consumer app for contraceptive use to prevent pregnancy https://go.usa.gov/xUHC6 

FDA - U.S. Food and Drug Administration

6-8-2018

Scientific guideline: ICH M9 on biopharmaceutics classification system based biowaivers - Step 2b - First version, draft: consultation open

This new multidisciplinary guideline is proposed to address biopharmaceutics classification system (BCS)-based biowaivers. BCS-based biowaivers may be applicable to BCS Class I and III drugs, however BCS-based biowaivers for these two classes are not recognized worldwide. This means that pharmaceutical companies have to follow different approaches in the different regions. This guideline will provide recommendations to support the biopharmaceutics classification of medicinal products and will provide rec...

Europe - EMA - European Medicines Agency

27-7-2018

Scientific guideline: Draft VICH GL58 Stability testing of new veterinary drug substances and medicinal products in climatic zones III and IV - First version, draft: consultation open

The guideline is an annex to the VICH parent stability guideline, stability testing of new veterinary drug substances and medicinal products (VICH GL3 (R)), and provides guidance regarding the stability data package for a new veterinary drug substance and medicinal product to be included in a registration application submitted within the regions in the climatic zones III and IV.

Europe - EMA - European Medicines Agency

16-7-2018

News and press releases: EMA’s proactive publication of clinical data a success

First report on unprecedented transparency policy shows high user satisfaction

Europe - EMA - European Medicines Agency

5-7-2018

International work-sharing pilot - Apalutamide (Erlyand)

Apalutamide (Erlyand) is the first medicine approved via ACSS Consortium’s NCE working group

Therapeutic Goods Administration - Australia

29-6-2018

News and press releases: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 June 2018

Nine medicines recommended for approval, including the first two CAR-T cell therapies in the EU

Europe - EMA - European Medicines Agency

29-6-2018

News and press releases: First two CAR-T cell medicines recommended for approval in the European Union

Development of Kymriah and Yescarta supported through PRIME

Europe - EMA - European Medicines Agency

22-6-2018

News Release: #FDA permits marketing of first catheter-based systems used to create vascular access for hemodialysis patients https://go.usa.gov/xUqu9  #medicaldevice

News Release: #FDA permits marketing of first catheter-based systems used to create vascular access for hemodialysis patients https://go.usa.gov/xUqu9  #medicaldevice

FDA - U.S. Food and Drug Administration

22-6-2018

News and press releases: Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 19–21 June 2018

First stem cell-based veterinary medicine recommended for marketing authorisation

Europe - EMA - European Medicines Agency

22-6-2018

News and press releases: First stem cell-based veterinary medicine recommended for marketing authorisation

Arti-Cell Forte is indicated in horses with mild to moderate lameness due to joint inflammation

Europe - EMA - European Medicines Agency

22-6-2018

First continuous glucose monitoring system that includes a fully implantable glucose sensor that can be worn up to 90 days approved today. #cgm #diabetes #fda #medicaldevice https://go.usa.gov/xUqg5 pic.twitter.com/6zs99z2Dlz

First continuous glucose monitoring system that includes a fully implantable glucose sensor that can be worn up to 90 days approved today. #cgm #diabetes #fda #medicaldevice https://go.usa.gov/xUqg5  pic.twitter.com/6zs99z2Dlz

FDA - U.S. Food and Drug Administration

4-6-2018

Australian Regulatory Guidelines for Advertising Therapeutic Goods (ARGATG)

First stage of the Australian Regulatory Guidelines for Advertising Therapeutic Goods

Therapeutic Goods Administration - Australia

1-6-2018

News and press releases: First monoclonal antibody therapy for prevention of migraine

Aimovig recommended for marketing authorisation

Europe - EMA - European Medicines Agency